5166 related articles for article (PubMed ID: 3384660)
21. Adjuvant interferon in high-risk melanoma: the AIM HIGH Study--United Kingdom Coordinating Committee on Cancer Research randomized study of adjuvant low-dose extended-duration interferon Alfa-2a in high-risk resected malignant melanoma.
Hancock BW; Wheatley K; Harris S; Ives N; Harrison G; Horsman JM; Middleton MR; Thatcher N; Lorigan PC; Marsden JR; Burrows L; Gore M
J Clin Oncol; 2004 Jan; 22(1):53-61. PubMed ID: 14665609
[TBL] [Abstract][Full Text] [Related]
22. Randomized controlled trial of adjuvant chemoimmunotherapy with DTIC and BCG after complete excision of primary melanoma with a poor prognosis or melanoma metastases.
Can Med Assoc J; 1983 Apr; 128(8):929-33. PubMed ID: 6339024
[TBL] [Abstract][Full Text] [Related]
23. Melanoma of the penis, scrotum and male urethra: a 40-year single institution experience.
Sánchez-Ortiz R; Huang SF; Tamboli P; Prieto VG; Hester G; Pettaway CA
J Urol; 2005 Jun; 173(6):1958-65. PubMed ID: 15879790
[TBL] [Abstract][Full Text] [Related]
24. Postsurgical adjuvant treatment of malignant melanoma patients by the thymic factor thymostimulin.
Azizi E; Brenner HJ; Shoham J
Arzneimittelforschung; 1984; 34(9):1043-7. PubMed ID: 6542371
[TBL] [Abstract][Full Text] [Related]
25. [Chemotherapy of malignant melanoma--current status].
Karg C; Garbe C; Orfanos CE
Hautarzt; 1990 Feb; 41(2):56-65. PubMed ID: 2180855
[TBL] [Abstract][Full Text] [Related]
26. Fotemustine compared with dacarbazine in patients with disseminated malignant melanoma: a phase III study.
Avril MF; Aamdal S; Grob JJ; Hauschild A; Mohr P; Bonerandi JJ; Weichenthal M; Neuber K; Bieber T; Gilde K; Guillem Porta V; Fra J; Bonneterre J; Saïag P; Kamanabrou D; Pehamberger H; Sufliarsky J; Gonzalez Larriba JL; Scherrer A; Menu Y
J Clin Oncol; 2004 Mar; 22(6):1118-25. PubMed ID: 15020614
[TBL] [Abstract][Full Text] [Related]
27. Lymph-vascular space invasion and number of positive para-aortic node groups predict survival in node-positive patients with endometrial cancer.
Watari H; Todo Y; Takeda M; Ebina Y; Yamamoto R; Sakuragi N
Gynecol Oncol; 2005 Mar; 96(3):651-7. PubMed ID: 15721407
[TBL] [Abstract][Full Text] [Related]
28. Prognostic variables for patients with stage III malignant melanoma.
Messaris GE; Konstadoulakis MM; Ricaniadis N; Leandros E; Androulakis G; Karakousis PC
Eur J Surg; 2000 Mar; 166(3):233-9. PubMed ID: 10755339
[TBL] [Abstract][Full Text] [Related]
29. Randomized phase 2/3 trial of CpG oligodeoxynucleotide PF-3512676 alone or with dacarbazine for patients with unresectable stage III and IV melanoma.
Weber JS; Zarour H; Redman B; Trefzer U; O'Day S; van den Eertwegh AJ; Marshall E; Wagner S
Cancer; 2009 Sep; 115(17):3944-54. PubMed ID: 19536884
[TBL] [Abstract][Full Text] [Related]
30. A randomized phase III study comparing dacarbazine, BCNU, cisplatin and tamoxifen with dacarbazine and interferon in advanced melanoma.
Middleton MR; Lorigan P; Owen J; Ashcroft L; Lee SM; Harper P; Thatcher N
Br J Cancer; 2000 Mar; 82(6):1158-62. PubMed ID: 10735499
[TBL] [Abstract][Full Text] [Related]
31. Systemic treatment of malignant melanoma: grade is as important as stage.
Retsas S
Clin Exp Dermatol; 1997 Mar; 22(2):67-71. PubMed ID: 9330068
[TBL] [Abstract][Full Text] [Related]
32. Phase II multicenter study of neoadjuvant biochemotherapy for patients with stage III malignant melanoma.
Lewis KD; Robinson WA; McCarter M; Pearlman N; O'Day SJ; Anderson C; Amatruda TT; Baron A; Zeng C; Becker M; Dollarhide S; Matijevich K; Gonzalez R
J Clin Oncol; 2006 Jul; 24(19):3157-63. PubMed ID: 16809738
[TBL] [Abstract][Full Text] [Related]
33. [Sentinel lymph node biopsy for melanoma: prognostic value and disadvantages in 300 patients].
de Vries M; Jager PL; Suurmeijer AJ; Plukker JT; van Ginkel RJ; Hoekstra HJ
Ned Tijdschr Geneeskd; 2005 Aug; 149(33):1845-51. PubMed ID: 16128183
[TBL] [Abstract][Full Text] [Related]
34. Lack of benefit of adjunctive chemotherapy in stage I malignant melanoma: a Southwest Oncology Group Study.
Tranum BL; Dixon D; Quagliana J; Neidhart J; Balcerzak SP; Costanzi JH; Fabian CJ; Neilan B; Maloney T; O'Bryan RM
Cancer Treat Rep; 1987 Jun; 71(6):643-4. PubMed ID: 3581104
[TBL] [Abstract][Full Text] [Related]
35. Combination chemotherapy (dacarbazine, carmustine, cisplastin, and tamoxifen) in advanced melanoma.
Tan EH; Ang PT
Singapore Med J; 1996 Apr; 37(2):165-7. PubMed ID: 8942255
[TBL] [Abstract][Full Text] [Related]
36. Eastern Cooperative Oncology Group studies with DTIC (NSC-45388).
Carbone PP; Costello W
Cancer Treat Rep; 1976 Feb; 60(2):193-8. PubMed ID: 769973
[TBL] [Abstract][Full Text] [Related]
37. Melanoma in children and the use of sentinel lymph node biopsy.
Bütter A; Hui T; Chapdelaine J; Beaunoyer M; Flageole H; Bouchard S
J Pediatr Surg; 2005 May; 40(5):797-800. PubMed ID: 15937817
[TBL] [Abstract][Full Text] [Related]
38. Evaluation of the prognostic significance of the site of origin of cutaneous melanoma.
Law MM; Wong JH
Am Surg; 1994 May; 60(5):362-6. PubMed ID: 8161088
[TBL] [Abstract][Full Text] [Related]
39. [Current results with surgery and adjuvant chemotherapy in malignant melanoma].
Mechl Z; Kopecný J
Arch Geschwulstforsch; 1986; 56(5):367-71. PubMed ID: 2429631
[TBL] [Abstract][Full Text] [Related]
40. Malignant melanoma--prognosis and actual treatment strategies with chemotherapy and biological response modifiers.
Bergmann L
Eur J Cancer Clin Oncol; 1989; 25 Suppl 3():S31-6. PubMed ID: 2697576
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]